Sarbajit Mukherjee, Chief of GI Medical Oncology at Miami Cancer Institute and Co-Chair of GI Clinical Trial Working Group at Hoosier Cancer Research Network, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Who truly benefits from perioperative immunotherapy in gastric and GEJ cancer?
Our latest data suggest the answer is clear: tumor biology matters.
I’m excited to share that our team’s meta-analysis has just been published in JNCI Cancer Spectrum, synthesizing evidence from 7 randomized trials and 2,510 patients evaluating perioperative chemo-immunotherapy in resectable gastric/GEJ adenocarcinoma.
Key findings:
- Adding immunotherapy to perioperative chemotherapy improves outcomes overall:
- pCR: 17.6% vs 6.1%
- EFS: HR 0.76
- OS: HR 0.82
However, benefit is biologically enriched:
- PD-L1–positive tumors show consistent improvement in pCR, EFS, and OS
- PD-L1–negative disease demonstrates no statistically significant survival signal at the meta-analysis level
Importantly, these findings align closely with the National Comprehensive Cancer Network (NCCN) guidelines.
Huge congratulations to Reo Omori and Yu Fujiwara for leading and completing this important work.”
Title: Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
Authors: Reo Omori, Yu Fujiwara, Kota Tokunaga, Takumi Sato, Sarbajit Mukherjee
Read the Full Article on JNCI Cancer Spectrum
More posts featuring Sarbajit Mukherjee.